BlackRock Capital Allocation Term Trust
No SEC Form 4 filings for $BCAT in the last 30 days.
See all $BCAT insider activity →BlackRock Capital Allocation Trust (BCAT) shares fell 4.2% premarket Friday after announcing a rights offering. Shareholders can buy additional shares at a discount to net asset value, with terms to be finalized in October 2026. The fund's board and adviser believe the offering is in shareholders' best interests to increase assets and seize investment opportunities.
Rieder Richard M sold 35,734 shares of BlackRock Capital Allocation Term Trust (BCAT) at $15.96 ($0.57M total) on 2026-07-13.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BCAT (BlackRock Capital Allocation Term Trust). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent BCAT coverage spans corporate actions and insider activity.
The rights issue dilutes existing shares but offers a discount, likely pressuring price short‑term.
Routine insider open-market sale with no 10b5-1 plan disclosed; may slightly affect sentiment but is not a fundamental catalyst.
AlphAI scores every news story that mentions BCAT with an AI model for sentiment and relevance, and aggregates insider trades from BlackRock Capital Allocation Term Trust's SEC EDGAR Form 4 filings. Figures refresh continuously.
BlackRock Capital Allocation Trust (BCAT) shares fell 4.2% premarket Friday after announcing a rights offering. Shareholders can buy additional shares at a discount to net asset value, with terms to be finalized in October 2026. The fund's board and adviser believe the offering is in shareholders' best interests to increase assets and seize investment opportunities.
2 min readRieder Richard M sold 35,734 shares of BlackRock Capital Allocation Term Trust (BCAT) at $15.96 ($0.57M total) on 2026-07-13.
2 min read